+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vancomycin Market - Global Forecast 2026-2032- Product Image
Vancomycin Market - Global Forecast 2026-2032- Product Image
New

Vancomycin Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 187 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889004
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The vancomycin market stands at a pivotal point, influenced by shifting care settings, regulatory scrutiny, and evolving procurement strategies. As clinical, operational, and commercial forces converge, industry leaders must realign to safeguard access and optimize therapeutic outcomes.

Market Snapshot: Vancomycin Market Overview

The Vancomycin Market grew from USD 779.23 million in 2025 to USD 820.86 million in 2026. It is projected to continue expanding at a CAGR of 5.12%, ultimately reaching USD 1.10 billion by 2032. This sustained growth reflects the ongoing clinical reliance on vancomycin, persistent antimicrobial resistance challenges, and the heightened focus on supply chain resilience and adaptable procurement in response to global disruptions and regulatory mandates.

Scope & Segmentation

This analysis delivers a comprehensive breakdown of the vancomycin market, structured to help senior decision-makers address diverse clinical and commercial needs.

  • Dosage Forms: Lyophilized powder for injection, oral formulations, and solutions for injection shape manufacturing and distribution requirements based on their stability and handling needs.
  • Routes of Administration: Intravenous and oral routes, each influencing specific pharmacy practices and patient management protocols.
  • Clinical Indications: Clostridioides difficile management, treatment of methicillin-resistant Staphylococcus aureus (MRSA), and surgical prophylaxis, with stewardship and guideline alignment varying per indication.
  • End Users: Ambulatory surgical centers (multi-specialty, single-specialty), clinics (outpatient, specialty), and hospitals (community, tertiary care), each setting demanding tailored product presentations and logistic solutions.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy, with each channel presenting unique regulatory and fulfillment dynamics.
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific, each with distinct regulatory frameworks, procurement systems, and manufacturing bases.
  • Technology Use: Application of therapeutic drug monitoring tools, serialization, traceability tech, and diagnostic innovations supporting evidence-driven use and operational transparency.

Key Takeaways

  • Clinical stewardship and rapid diagnostics are redefining how, when, and where vancomycin is used in routine and complex care pathways.
  • Migration to outpatient and decentralized settings is reshaping demand for flexible packaging, smaller volumes, and more responsive logistics solutions.
  • Sustained regulatory scrutiny increases the importance of robust quality systems, transparent inspection records, and supply continuity plans in supplier evaluation.
  • Collaborative contracts and risk-sharing arrangements between healthcare systems and suppliers are helping to mitigate supply chain fragility and input volatility.
  • Segment-driven strategies, such as distinct packaging for ambulatory centers versus hospital systems, are essential for market access and operational efficiency.
  • Company-level differentiators now rest on reliable supply, regulatory excellence, and integrated clinical support, rather than price alone.

Tariff Impact: Procurement & Supply Chain Adjustments

The introduction of 2025 tariff policies has added new complexity to the vancomycin supply chain. These tariffs prompt manufacturers and distributors to revisit sourcing strategies, often increasing inventory buffers and accelerating regionalization or nearshoring of production to offset cost volatility. Procurement teams are adapting by favoring suppliers with domestic or regionally diversified manufacturing and extending purchasing cycles to hedge against tariff-driven disruptions. Regulatory authorities maintain a close watch to ensure drug quality and access remain unaffected by these commercial shifts. The intersection of these factors is leading to more transparent contingency planning and revised procurement approaches throughout the value chain.

Methodology & Data Sources

This report’s insights are grounded in a structured review of clinical guidelines, regulatory communications, peer-reviewed literature, and supply-chain policy announcements. Direct interviews with clinicians, pharmacists, and supply-chain leaders ensure the findings reflect current operational conditions and best practices. Both quantitative and qualitative synthesis methods confirm the validity of the conclusions.

Why This Report Matters

  • Equips industry stakeholders to anticipate and respond to regulatory shifts, supply chain changes, and clinical practice updates that drive vancomycin utilization.
  • Enables more informed procurement, contracting, and delivery planning based on segmentation, regional dynamics, and evolving buyer expectations.
  • Supports proactive risk management and sustained patient access by highlighting actionable, evidence-based strategies for supply resilience and stewardship.

Conclusion

A strategic approach to vancomycin market participation demands alignment across stewardship, supply reliability, and tailored logistics. Fostering collaboration and operational transparency will be central to ensuring continued access and clinical value across evolving care landscapes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Vancomycin Market, by Dosage Form
8.1. Lyophilized Powder For Injection
8.2. Oral Formulation
8.3. Solution For Injection
9. Vancomycin Market, by Indication
9.1. Clostridioides Difficile Infections
9.2. Methicillin Resistant Staphylococcus Aureus Treatment
9.3. Surgical Prophylaxis
10. Vancomycin Market, by Route Of Administration
10.1. Intravenous
10.2. Oral
11. Vancomycin Market, by End User
11.1. Ambulatory Surgical Centers
11.1.1. Multi Specialty Centers
11.1.2. Single Specialty Centers
11.2. Clinics
11.2.1. Outpatient Clinics
11.2.2. Specialty Clinics
11.3. Hospitals
11.3.1. Community Hospitals
11.3.2. Tertiary Care Hospitals
12. Vancomycin Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Vancomycin Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Vancomycin Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Vancomycin Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Vancomycin Market
17. China Vancomycin Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Alkem Laboratories Ltd.
18.6. Alvogen, Inc.
18.7. Amneal Pharmaceuticals, Inc.
18.8. ANI Pharmaceuticals, Inc.
18.9. Aphios Corporation
18.10. Aurobindo Pharma Limited
18.11. Azurity Pharmaceuticals, Inc.
18.12. Baxter International Inc.
18.13. Cellceutix Corporation
18.14. China National Pharmaceutical Group Co., Ltd
18.15. Dr. Reddy’s Laboratories Ltd.
18.16. Fresenius Kabi AG
18.17. Glenmark Pharmaceuticals Ltd.
18.18. Helix BioMedix, Inc.
18.19. Hikma Pharmaceuticals PLC
18.20. LegoChem Biosciences Inc.
18.21. Lytix Biopharma AS
18.22. Novartis AG
18.23. Pfizer Inc.
18.24. Slate Run Pharmaceuticals, Inc.
18.25. Sun Pharmaceutical Industries Ltd.
18.26. Teva Pharmaceutical Industries Ltd.
18.27. Viatris Inc.
18.28. Xellia Pharmaceuticals ApS
List of Figures
FIGURE 1. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS VANCOMYCIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. EUROPE VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. EUROPE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 109. EUROPE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. EUROPE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. EUROPE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 127. AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 131. AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 132. AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 133. AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. ASEAN VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. ASEAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 146. ASEAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 147. ASEAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. ASEAN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. ASEAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 150. ASEAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 151. ASEAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 152. ASEAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. GCC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GCC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 155. GCC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 156. GCC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. GCC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. GCC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 159. GCC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 160. GCC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 161. GCC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. BRICS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. BRICS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 173. BRICS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 174. BRICS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. BRICS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. BRICS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 177. BRICS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 178. BRICS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 179. BRICS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. G7 VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. G7 VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 182. G7 VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. G7 VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. G7 VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. G7 VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 186. G7 VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 187. G7 VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 188. G7 VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. NATO VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. NATO VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 191. NATO VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 192. NATO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. NATO VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. NATO VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 195. NATO VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 196. NATO VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 197. NATO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. CHINA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. CHINA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 210. CHINA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 211. CHINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. CHINA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. CHINA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
TABLE 214. CHINA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 215. CHINA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 216. CHINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Vancomycin market report include:
  • Alkem Laboratories Ltd.
  • Alvogen, Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • Aphios Corporation
  • Aurobindo Pharma Limited
  • Azurity Pharmaceuticals, Inc.
  • Baxter International Inc.
  • Cellceutix Corporation
  • China National Pharmaceutical Group Co., Ltd
  • Dr. Reddy’s Laboratories Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Helix BioMedix, Inc.
  • Hikma Pharmaceuticals PLC
  • LegoChem Biosciences Inc.
  • Lytix Biopharma AS
  • Novartis AG
  • Pfizer Inc.
  • Slate Run Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xellia Pharmaceuticals ApS

Table Information

Report AttributeDetails
No. of Pages187
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 820.86 Million
Forecasted Market Value ( USD ) by 2032 $ 1100 Million
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Vancomycin Hydrochloride Capsules Market - Global Forecast to 2030 - Product Image

Vancomycin Hydrochloride Capsules Market - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Vancomycin - Global Strategic Business Report - Product Image

Vancomycin - Global Strategic Business Report

  • Report
  • 159 Pages
  • Global
From
Vancomycin Market Report 2025 - Product Image

Vancomycin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Vancomycin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application - Product Image

Vancomycin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application

  • Report
  • 96 Pages
  • Global
From
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2025 - Product Image

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Market

Vancomycin is an antibiotic used to treat a wide range of bacterial infections. It is a glycopeptide antibiotic, derived from the bacterium Amycolatopsis orientalis, and is used to treat infections caused by Gram-positive bacteria. Vancomycin is often used as a last-resort antibiotic, when other antibiotics have failed to treat an infection. It is also used to treat infections caused by Clostridium difficile, a bacterium that can cause severe diarrhea. Vancomycin is available in both oral and intravenous forms, and is used to treat a variety of infections, including skin and soft tissue infections, bone and joint infections, and endocarditis. It is also used to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is a widely used antibiotic, and is available from a number of pharmaceutical companies, including Pfizer, Merck, and AstraZeneca. It is also available in generic form from a number of generic drug manufacturers. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.